Lv11
48 积分 2024-03-23 加入
Immunostimulation with chemotherapy in the era of immune checkpoint inhibitors
11天前
已完结
Paradigms on Immunotherapy Combinations with Chemotherapy
11天前
已完结
The changing treatment landscape of EGFR-mutant non-small-cell lung cancer
1个月前
已完结
Elucidating the complexity of radiation-induced brain injury: comprehensive assessment of hippocampal and cortical impacts
1个月前
已完结
Treatment of NSCLC after chemoimmunotherapy — are we making headway?
3个月前
已完结
Elevated serum magnesium levels prompt favourable outcomes in cancer patients treated with immune checkpoint blockers
3个月前
已完结
Sintilimab plus bevacizumab biosimilar IBI305 and chemotherapy for patients with EGFR-mutated non-squamous non-small-cell lung cancer who progressed on EGFR tyrosine-kinase inhibitor therapy (ORIENT-31): first interim results from a randomised, double-blind, multicentre, phase 3 trial
4个月前
已完结
Genomic profiling and prognostic factors of leptomeningeal metastasis in EGFR-mutant NSCLC after resistant to third-generation EGFR-tyrosine kinase inhibitors
4个月前
已完结
Delineation of the primary tumour Clinical Target Volumes (CTV-P) in laryngeal, hypopharyngeal, oropharyngeal and oral cavity squamous cell carcinoma: AIRO, CACA, DAHANCA, EORTC, GEORCC, GORTEC, HKNPCSG, HNCIG, IAG-KHT, LPRHHT, NCIC CTG, NCRI, NRG Oncology, PHNS, SBRT, SOMERA, SRO, SSHNO, TROG consensus guidelines
6个月前
已完结
Durable response to osimertinib in EGFR mutated T790M wildtype non-small cell lung cancer with leptomeningeal metastases: A case report
6个月前
已完结
皖公网安备34019202002308
